| Stereochemistry | RACEMIC |
| Molecular Formula | C14H16N6O |
| Molecular Weight | 284.3164 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN\C(NC#N)=N/C1=CC=C(C=C1)C2=NNC(=O)CC2C
InChI
InChIKey=NUHPODZZKHQQET-UHFFFAOYSA-N
InChI=1S/C14H16N6O/c1-9-7-12(21)19-20-13(9)10-3-5-11(6-4-10)18-14(16-2)17-8-15/h3-6,9H,7H2,1-2H3,(H,19,21)(H2,16,17,18)
| Molecular Formula | C14H16N6O |
| Molecular Weight | 284.3164 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 1 |
| Optical Activity | ( + / - ) |
Siguazodan is a selective inhibitor of phosphodiesterase 3. It caused significant increases in cardiac output and stroke volume. It is orally active inotropic/vasodilator agent with a sustained duration in vivo. Siguazodan has potential utility in the treatment of congestive heart failure. Siguazodan has anti-platelet actions over the same concentration range that it is an inotrope and vasodilator. Siguazodan caused bronchodilation. In combination with phosphodiesterase 4, it may be useful in the therapy of asthma.
CNS Activity
Originator
Approval Year
PubMed
Sample Use Guides
Among the ways in which cyclic AMP inhibits platelet function is a reduction in signal transduction and in Ca2+ mobilization. Therefore examined the effect of siguazodan on stimulated increases in [Ca2+]i in quin 2-loaded platelets
resuspended in HEPES-buffered saline was examined. Siguazodan, was able to inhibit almost completely the [Ca2+]i elevation evoked by 20 uM ADP. The calculated ICjo for this effect was 1.5 uM
